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I am writing now with the results of your routine annual testing. We hope this information will help you and your health care provider to develop a plan to keep you healthy and reduce your risk for another stroke and heart disease.
The enclosed results were obtained at the time of your annual in-person interview. At that time, we asked you about risk factors for stroke, like cigarette smoking and heavy alcohol use. We also asked about your exercise habits and about any current treatments you were using to prevent another stroke. We measured your blood pressure and weight and tested your blood for evidence of high blood sugar, liver problems, high cholesterol and high triglycerides. The enclosed Annual Report shows your results, along with goals and recommendations to protect your health and help prevent another stroke or a heart attack.
At your request a copy of this letter has been sent to your personal health care provider. We encourage you to discuss this information with your health care provider, who can advise you if any additional action or testing is needed.
Thank you again for participating in this research. We are very grateful for your generous involvement in this international effort to improve the health of all patients after a stroke or transient ischemic attack (TIA). Your involvement will have a lasting impact on quality of care for thousands of other patients.
If you have any questions about the IRIS trial, please feel free to contact us. BLOOD PRESSURE: See your doctor within a few weeks for adjustment of your blood pressure medications. Your blood pressure was too high when we measured it.
LIPID RESULTS: Review the lipid results with your health care provider to consider changes in your cholesterol-lowering medication. Your LDL cholesterol may be too high (actual goals depend on your individual risk factors for heart disease and stroke).
ANTIPLATELET USE: Talk with your health care provider about taking aspirin or another antiplatelet medication. These medications may prevent future strokes in patients with a recent stroke or TIA.
CIGARETTE SMOKING: Do everything you can to stop smoking. You might ask your health care provider about medications to help you quit smoking. We have enclosed a brochure designed to help you stop smoking.
BONE HEALTH: Aim to get the recommended amounts of calcium & vitamin D through diet or supplements to reduce your risk of bone fracture. You can also strengthen your bones and protect blood vessels by regular exercise and avoiding excessive alcohol use.
The American Osteoporosis Foundation recommends bone mineral density testing for all men over age 69 and women over age 64. PATIENT NAME is enrolled in the Insulin Resistance Intervention after Stroke (IRIS) Trial, a randomized placebo-controlled clinical trial funded by the National Institutes of Health. The research objective for IRIS is to test the effectiveness of pioglitazone (Actos) compared with placebo for prevention of recurrent stroke and myocardial infarction among non-diabetic patients with ischemic stroke or transient ischemic attack (TIA) and insulin resistance. The trial has enrolled XXXX participants from about 160 research centers throughout the world.
We are in frequent contact with each IRIS participant to monitor study endpoints, medication adherence and adverse events. Once a year, we complete a brief physical examination, repeat the ALT test, and measure vascular risk factors, including glucose and cholesterol.
We recently completed this testing for PATIENT NAME and have sent the participant a copy of the results. I am enclosing a copy of my letter. We have encouraged PATIENT NAME to contact you for any values that are indicated as not meeting the listed treatment goals. 
The IRIS Trial Secondary Prevention Goals
For lipid management, the IRIS goal for low-density lipoprotein (LDL) of less than 2.59 mmol/L was based on 2001 NCEP guidelines. 1 In 2008, the AHA revised its approach by recommending high-intensity statin therapy after atherosclerotic stroke or TIA in patients without known coronary heart disease (CHD). 2 Although statin therapy was not reported back to IRIS participants in their results letters, we describe statin use in this population in addition to achievement of LDL <2.59 mmol/L to reflect this revised approach.
For patients with ischemic stroke or TIA with atrial fibrillation, oral anticoagulation with vitamin K antagonists (VKA) was recommended at the time IRIS began enrolling 3 and remained the primary anticoagulation therapy for these patients until 2014 when the AHA allowed apixaban and dabigatran as Class I alternatives to VKA therapy. 4 IRIS participants were told that an anticoagulant is advisable for stroke or TIA patients with atrial fibrillation unless there is a contraindication.
In 2005 it was broadly recognized that all patients with non-cardioembolic stroke should receive aspirin monotherapy. 3, 5 In 2008, the AHA revised its approach to allow clopidogrel monotherapy and the combination of aspirin and extended-release dipyridamole as Class I alternatives to aspirin monotherapy. 2 The IRIS trial anticipated these changes by advising any participant not taking an anticoagulant to take an antiplatelet agent such as aspirin, clopidogrel, or combined sustained-release dipyridamole-aspirin. IRIS participants were considered at goal for use of antithrombotic therapy if they were taking either an anticoagulant or an antiplatelet medication.
Guidelines for management of blood pressure, body weight, cigarette smoking, alcohol use, and aerobic exercise participation were unchanged during the trial. IRIS goals were defined as: blood pressure <140/90 mm Hg, 3, 6 body mass index (BMI) 18-25 kg/m 2 , 7 abstinence from cigarette smoking, 3 safe alcohol use (≤2 drinks/day for men and ≤1 drink/day for women), 7 and aerobic exercise [large-muscle activities (e.g., walking, treadmill, stationary cycle, combined arm-leg ergometry, arm ergometry, seated stepper)] at least three days/week for a minimum total of 20 minutes/day. †Clinical history variables were defined as follows: stroke or TIA, see entry criteria; hypertension, self-report; hyperlipidemia, self-report; coronary artery disease, self-report history of myocardial infarction, coronary-artery bypass graft, or coronary stent insertion; congestive heart failure, self-report; atrial fibrillation, history of AF on baseline electrocardiogram as determined by site investigator; peripheral vascular disease, self-report; current smoking, self-report. (Uncertain selfreport ='no'.) ‡The homeostasis model assessment (HOMA) is an index of insulin resistance based on fasting insulin and glucose values. A HOMA over 3.0 was used to identify patients with insulin resistance in the IRIS trial. Baseline  2592  87  41  10  31  10  8  0  0  20  19  Year 1  2529  343  322  261  298  206  190  189  176  184  188  Year 2  2455  532  501  422  448  263  256  250  249  256  258  Year 3  2260  578  552  476  481  291  277  281  265  275 Baseline  178  3  0  0  0  0  0  0  0  2  1  Year 1  175  13  8  7  8  6  8  5  5  7  5  Year 2  174  13  11  10  11  9  9  8  8  9  8  Year 3  166  23  19  17  19  14  13  13  13  15  14   GERMANY   Baseline  151  14  2  0  2  0  0  0  0  8  4  Year 1  146  14  10  6  10  3  3  3  3  5  5  Year 2  144  16  13  10  13  4  3  2  2  5  2  Year 3  123  26  19  14  18  9  6  6  5  12  5   ALL   Baseline  3718  126  51  12  38  12  10  1  0  43  24  Year 1  3639  460  414  322  387  253  235  231  217  240  238  Year 2  3543  657  612  506  553  322  303  295  293  313  302  Year 3  3255  742  695  579  616  360  335  339  323  347 †Antithrombotic therapy includes antiplatelet or anticoagulation therapies. ‡Safe alcohol use was defined as ≤2 drinks/day for males and ≤1 drink/day for females. 7 §Aerobic exercise was defined as large-muscle activities at least 3 days/week for a total of 20 minutes/day. †OR for being at goal if enrolled from specified country vs enrolled from another country. ‡Logistic model adjusted for male sex, white race, marital status (married/with partner vs not), smoking status (non-smoker vs smoker) and baseline 3MS score.
